Antibody responses after dose-sparing intradermal influenza vaccination
Antibody responses after dose-sparing intradermal influenza vaccination
复制标题
DOI：
10.1016/j.vaccine.2006.08.026
复制
发表时间：
2007-01-08
期刊：
影响因子：
5.5
通讯作者：
Thongcharoen, Prasert
中科院分区：
文献类型：
--
作者：
Auewarakul, Prasert;Kositanont, Uraiwan;Thongcharoen, Prasert
减少剂量的皮内（ID）流感疫苗接种是一种有吸引力的方法，以增加疫苗供应的情况下，疫苗短缺。我们进行了一项随机开放标签研究，其中500名受试者被随机分配接受0.1 ml剂量的灭活裂解病毒流感疫苗ID注射或0.5 rut剂量的IM注射。接种后第28天，ID组和IM组中血凝抑制（HI）抗体滴度至少为1：40的受试者分别为93.3%和98.0%（针对甲型流感（HIN 1）病毒）。A（H3N2）病毒为86.3%对95.0%，B型流感病毒为43.5%对57.0%。ID组受试者在第28天的H1N1毒株、H3N2毒株和B毒株的几何平均滴度分别增加了16倍、8倍和2倍，而IM组分别增加了31倍、20倍和3倍。ID组受试者的局部反应显著高于IM组，但反应轻微且短暂。在本研究中，与全剂量IM注射相比，ID给予五分之一剂量的流感疫苗引起的抗体应答水平显著较低。然而，ID疫苗接种引起的抗体反应仍然足够高，足以满足欧洲专利药品委员会（CPMP）关于流感疫苗年度残留的要求指南。(c)2006爱思唯尔有限公司保留所有权利。
Reduced-dose intradermal (ID) influenza vaccination is an attractive approach to increase availability of vaccine supply in an event of vaccine shortage. We conducted a randomized open-label Study, in which 500 Subjects were randomly assigned to receive an ID injection of 0.1 ml dose of inactivated split-virion influenza vaccine or an IM injection of 0.5 rut dose. The Subjects who had hemagglutination inhibition (HI) antibody titer of at least 1:40 at day 28 post-vaccination in ID and IM groups were 93.3% versus 98.0% for influenza A(H IN 1) virus. 86.3% versus 95.0% for A(H3N2) Virus, and 43.5% Versus 57.0% for influenza B virus. Subjects in the ID group had an increase in geometric mean titer by a factor of 16 for the H1N1 strain, 8 for the H3N2 strain, and 2 For the B strain on day 28, as compared with respective increase in the IM group of 31, 20, and 3. Local reactions were significantly more frequent among subjects in the ID group than those in the IM group, but the reactions were mild and transient. In this study, ID administration of one-fifth dose of influenza vaccine elicited significantly lower levels of antibody response as compared to full-dose IM injection. However, the antibody responses elicited by the ID vaccination were still sufficiently high to meet the requirement guidelines of the European Committee for Proprietary Medicinal Products (CPMP) for the annual relicensure of influenza vaccines. (c) 2006 Elsevier Ltd. All rights reserved.